Table 1 Baseline Patient Demographic and Clinical Characteristics
N = 45 | |
|---|---|
Age (years) | |
Median | 69 |
(Range) | (51–86) |
Race | |
Caucasian | 39 (86.7%) |
African-American | 4 (8.9%) |
Asian | 1 (2.2%) |
Hispanic | 1 (2.2%) |
Baseline PSA (ng/mL) | |
Median | 57.6 |
(Range) | (5.4-457) |
Gleason Sum | |
≤ 7 | 11 (24.4%) |
8 | 8 (17.8%) |
9 | 18 (40.0%) |
10 | 5 (11.1%) |
Unknown | 3 (6.7%) |
Visceral Disease | |
Yes | 7 (15.6%) |
No | 38 (84.4%) |
Lines of Prior Novel AR Targeted Therapy | |
1 | 21 (46.7%) |
≥2 | 24 (53.3%) |
Prior Taxane Chemotherapy | |
Yes | 20 (44.4%) |
No | 25 (55.6%) |
≥ 2 Novel AR Targeted Therapy AND Prior Taxane Chemotherapy | |
Yes | 15 (33.3%) |
No | 30 (66.7%) |
